Source: Cytiva
Gene therapies are moving beyond rare diseases into more common conditions like Alzheimer’s and diabetes, but sky-high costs and manufacturing limits threaten widespread access. This article explores how Cytiva and industry leaders are tackling these challenges by improving viral vector production, increasing scalability, and optimizing processes to lower costs.
Read the full article to see how advances in manufacturing and industry collaboration could make gene therapy more affordable and available to those who need it most.
Offered Free by: Cell & Gene
See All Resources from: Cell & Gene
